Autoimmune hepatitis and overlap syndromes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Vogel, Arndt ^a   Wedemeyer, Heiner ^a   Manns, Michael P ^a   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Autoimmune hepatitis; Autoimmune polyendocrinopathy candiasis ectodermal dystrophy syndrome; Liver kidney microsomal autoantibodies; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID; VITAMIN D;

ALGORITHM; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; SCLEROSING CHOLANGITIS; STEROID THERAPY;

EID: 0036456932     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.33.x     Document Type: Conference Paper

References (89)

1. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 1998; 33: 99-103.
2. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999; 31: 929-38.
3. Manns MP, Strassburg CP. Autoimmune hepatitis: Clinical challenges. Gastroenterology 2001; 120: 1502-17.
4. Gregorio GV, Portman B, Reid F et al. Autoimmune hepatitis in childhood: A 20-year experience. Hepatology 1997; 25: 541-7.
5. Benten D, Widjaja A, von Depka M et al. Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy. Z. Gastroenterol. 2001; 39: 837-40.
6. Strassburg CP, Manns MP. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease. J. Hepatol. 1999; 31: 751.
7. Strassburg CP, Alex B, Zindy F et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J. Hepatol. 1996; 25: 859-66.
8. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest. 1991; 88: 1370-8.
9. Obermayer-Straub P, Strassburg C, Clemente M-G, Philipp T, Tukey RH, Manns MP. Recognition of three different epitopes on UDP-glucuronosyltransferases by LKM-3 antibodies in patients with autoimmune hepatitis and hepatitis D. Gut 1995; 37: A100.
10. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; I: 292-4.
11. Wies I, Brunner S, Henninger J et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-15.
12. Manns MP, Krüger M. Genetics in liver diseases. Gastroenterology 1994; 106: 1676-97.
13. Czaja AJ, Strettell M, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
14. Czaja AJ, Cassani F, Catala M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence type 1 autoimmune hepatitis. Dig. Dis. Sci. 1997; 8: 1688-96.
15. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR 4 and A1-B8-DR-3 are independent risk factors. Hepatology 1991; 13: 701-6.
16. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-7.
17. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816-22.
18. Cookson S, Constantini PK, Clare M et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851-6.
19. Scully LJ, Toze C, Sengar DPS, Goldstein R. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993; 104: 1478-84.
20. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyteantigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49-53.
21. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum. Immunol. 2001; 62: 1356-62.
22. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-31.
23. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: Evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001; 33: 1047-52.
24. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg GM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-17.
25. Targan SR, Landers C, Vidrich A, Czaja AJ. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-66.
26. Wächter B, Kyriasoulis A, Lohse AW, Gerken G, Meyer zum Büschenfelde KH, Manns M. Characterization of liver cytokeratin as a major antigen of anti-SLA antibodies. J. Hepatol. 1990; 11: 232-9.
27. Volkmann MML, Bäurle A, Heid H et al. Soluble liver antigen: Isolation of a 35 kD recombinant protein (SLA-P35) specifically recognizing sera from patients with autoimmune hepatitis type 3. Hepatology 2001; 33: 591-6.
28. Löhr H, Treichel U, Poralla T, Manns M, Meyer zum Büschenfelde K-H, Fleischer B. The human hepatic asia-loglycoprotein receptor is a target antigen for liver infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 1990; 12: 1314-20.
29. Treichel U, Gerken G, Rossol S, Rotthaue HW, Meyer zum Büschenfelde K-H, Portalla T. Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis. J. Hepatol. 1993; 19: 55-63.
30. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-6.
31. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73.
32. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-72.
33. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954-6.
34. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 1990; 11: 606-12.
35. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-6.
36. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.
37. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol. 1999; 30: 394-401.
38. Kanzler S, Weidemann C, Gerken G et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J. Hepatol. 1999; 31: 635-40.
39. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with anti-liver/kidney microsome type 1: A second type of 'autoimmune' hepatitis. Hepatology 1987; 7: 1333-9.
40. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins on patients with autoimmune hepatitis. Hepatology 1994; 19: 609-15.
41. Marcos Y, Fainboim HA, Capucchio M et al. Two locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis. Hepatology 1994; 19: 1371-4.
42. Seki T, Ota M, Furuta S et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103: 1041-7.
43. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-83.
44. Read AE, Sherlock S, Harrison CV. Active juvenile cirrhosis considered as part of a systemic disease associated and the effect of corticosteroid therapy. Gut 1963; 4: 378-93.
45. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
46. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J. Hepatol. 1993; 18: 15-23.
47. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OF. Autoimmune hepatitis in older patients. Age Ageing 1997; 26: 441-4.
48. Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am. J. Gastroenterol. 2001; 96: 1587-91.
49. Broome UOR, Loof L, Bodemar G et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-15.
50. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig. Dis. Sci. 2000; 45: 1944-8.
51. Burroughs AK, Bassendine MF, Thomas HC, Sherlock S. Primary liver cell cancer in autoimmune chronic liver disease. BMJ 1981; 282: 273.
52. Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1968; 55: 724-9.
53. Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
54. Cooksley WGE, Bradbear RA, Robinson W et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986; 6: 345-8.
55. Manns MP, Strassburg CP. Autoimmune hepatitis. In: O'Grady JG, Lake JR, Howdle DP, eds. Comprehensive Clinical Hepatology. London: Mosby, 2000; 16.1-14.
56. Sanchez-Urdazpal L, Czaja AJ, Van Holk B. Prognostic features and role of liver transplantation in severe corticoid-treated autoimmune chronic active hepatitis. Hepatology 1991; 15: 215-21.
57. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: Dose titration, standard dose and combination with azathioprine compound. Gut 1975; 16: 876-83.
58. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13.
59. Danielson A, Prytz H. Oral budesonide for treatment of autoimmune chronic hepatitis. Aliment. Pharmacol. Ther. 1994; 8: 585-90.
60. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-16.
61. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev. Esp. Enferm. Dig. 1999; 91: 630-8.
62. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J. Hepatol. 1994; 21: 1040-7.
63. Jackson LD, Song E. Cyclosporn in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
64. Alvarez F, Ciocca M, Canero-Velasco C et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J. Hepatol. 1999; 30: 222-7.
65. Debray D, Maggiore G, Giradet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatits. J. Pediatr. 1999; 135: 111-14.
66. Fernandez NF, Redeker AG, Vierling JM, Villamil FG, Fong T-L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol. 1999; 94: 241-8.
67. Van Thiel DH, Wright H, Carroll P et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am. J. Gastroenterol. 1995; 90: 771-6.
68. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J. Hepatol. 2000; 33: 371-5.
69. Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde K-H, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis: Report of three cases. Z. Gastroenterol. 1996; 35: 571-8.
70. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-15.
71. Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 1998; 13: 490-5.
72. van Hoogstraten HJ, Vleggaar FP, Boland GJ et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am. J. Gastroenterol. 2000; 95: 2015-22.
73. Samuel D, Figueiro J, Bismuth H. Liver transplantation: Indications and patient selection. In: O'Grady J, Lake JR, Howdle PD, eds. Comprehensive Clinical Hepatology. London: Mosby, 2000; 34.1-17.
74. Tillmann HL, Jackel E, Manns MP. Liver transplantation in autoimmune liver disease: Selection of patients. Hepatogastroenterology 1999; 46: 3053-9.
75. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J. Hepatol. 2000; 33: 163-6.
76. Narumi S, Hakamada K, Sasaki M et al. Liver transplantation for autoimmune hepatitis: Rejection and recurrence. Transplant. Proc. 1999; 31: 1955-6.
77. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl. Surg. 1999; 5: S30-6.
78. Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32: 693-700.
79. Wright HL, Bou-Abboud CF, Hassanenstein T et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136-9.
80. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation: When non-self becomes self. Hepatology 2000; 32: 868-70.
81. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68: 253-6.
82. Prados E, Cuervas-Mons V, De La Mata M et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998; 66: 1645-50.
83. Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. J. Hepatol. 1999; 30: 131-41.
84. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-5.
85. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: The result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107: 1839-43.
86. Johnson PJ, McFarlane IG. Meeting report: International autoimmune hepatitis group. Hepatology 1993; 18: 998-1005.
87. Strassburg CP, Jaeckel E, Manns MP. Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 1999; 11: 595-601.
88. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 10-15.
89. Michieletti P, Wanless IR, Katz A et al. Antimitochondrial antibody negative primary biliary cirrhosis: A distinct syndrome of autoimmune cholangitis. Gut 1994; 35: 260-5.